Neurocrine Biosciences, Inc.
DE ˙ DB ˙ US64125C1099
134,65 € ↑0,30 (0,22%)
2026-06-03
DEL PRIS
SecurityDE:NB3 / Neurocrine Biosciences, Inc.
InstitutionOppenheimer & Co Inc
Latest Disclosed Ownership42,079 shares
Latest Disclosed Value $ 5,543,487
Oppenheimer & Co Inc reports 3.67% increase in ownership of NB3 / Neurocrine Biosciences, Inc.

On April 23, 2026 - Oppenheimer & Co Inc filed a 13F-HR form disclosing ownership of 42,079 shares of Neurocrine Biosciences, Inc. (DE:NB3) valued at $4,702,328 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 40,591 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 3.67% during the quarter. The current value of the position is $5,665,937 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-23 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 42,079 1,488 3.67 5,543 -3.72 0.0675
2026-02-02 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,591 -432 -1.05 5,757 -0.02 0.0817
2025-11-06 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 41,023 625 1.55 5,759 13.41 0.0702
2025-07-31 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,398 21,010 108.37 5,078 136.80 0.0672
2025-04-23 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,388 447 2.36 2,144 -17.06 0.0324
2025-02-05 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,941 -348 -1.80 2,585 16.34 0.0386
2024-11-05 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,289 2,051 11.90 2,222 -6.36 0.0339
2024-08-08 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,238 283 1.67 2,373 1.50 0.0377
2024-05-07 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,955 -214 -1.25 2,338 3.36 0.0388
2024-02-13 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,169 249 1.47 2,262 18.86 0.0416
2023-11-08 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,920 437 2.65 1,904 22.46 0.0393
2023-08-03 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,483 25 0.15 1,554 -6.67 0.0311
2023-05-10 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,458 -3,539 -17.70 1,666 -30.28 0.0353
2023-02-08 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,997 1,473 7.95 2,388 21.40 0.0544
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,524 6,257 51.01 1,967 64.46 0.0460
2022-08-08 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,267 145 1.20 1,196 5.28 0.0257
2022-05-12 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,122 -164 -1.33 1,136 8.60 0.0205
2022-02-02 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,286 6,423 109.55 1,046 86.12 0.0183
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,863 183 3.22 562 1.63 0.0105
2021-08-03 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,680 1,781 45.68 553 45.91 0.0099
2021-05-10 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,899 -16 -0.41 379 1.07 0.0076
2021-02-11 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,915 128 3.38 375 3.02 0.0079
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,787 768 25.44 364 -1.36 0.0091
2020-08-11 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,019 -284 -8.60 369 29.02 0.0095
2020-05-08 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,303 -3,264 -49.70 286 -59.49 0.0087
2020-02-07 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,567 603 10.11 706 31.47 0.0175
2019-10-31 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,964 3,270 121.38 537 136.56 0.0146
2019-08-09 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,694 -4,195 -60.89 227 -62.60 0.0062
2019-04-24 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,889 1,773 34.66 607 66.30 0.0162
2019-01-29 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,116 -1,329 -20.62 365 -53.91 0.0114
2018-10-26 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,445 3,068 90.85 792 138.55 0.0202
2018-08-10 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,377 -159 -4.50 332 13.31 0.0090
2018-05-01 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,536 -9,664 -73.21 293 136.29 0.0075
2014-02-12 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,200 13,200 124 0.0040
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.